for CSIMarket.com :’
Natera’s Signatera Validated for Clinical Utility in Merkel Cell Carcinoma Amid Launch of New Cancer Trial’
Austin, Texas’ - Natera Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, has announced promising results from a new multicenter prospective study published in the Journal of Clinical Oncology. The study underscores the clinical utility of Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera, in the surveillance of Merkel cell carcinoma (MCC).
Merkel cell carcinoma is an aggressive form of skin cancer, characterized by a high mortality rate and a recurrence rate of 40% within five years. Early detection and precise monitoring are critical for effective management and improving patient outcomes. The new study demonstrates that Signatera’s MRD test, which uses a viral and tumor-informed approach, is effective for monitoring patients with MCC. This revelation holds substantial potential for improving patient surveillance and care strategies in this high-risk cancer population.
The full study, available in the Journal of Clinical Oncology, outlines the methodology and results, further solidifying Signatera’s role in offering personalized insights into cancer recurrence and providing critical data that can inform treatment decisions.
In parallel with the MCC study, Natera has announced the initiation of a new clinical trial focused on gastroesophageal cancer, named DECIPHER (Developing ctDNA Guided Adjuvant Therapy for Gastroesophageal Cancer). This Phase II, single-arm adjuvant trial will use the Signatera test to guide patient selection and assess the rate of MRD clearance in patients undergoing treatment for gastroesophageal cancer. The DECIPHER trial aims to leverage the tumor-informed MRD testing to potentially transform the therapeutic landscape for another challenging cancer type.
Natera’s expanding portfolio of clinical studies and trials reflects an ongoing commitment to advancing the use of ctDNA and genetic testing in oncology. By providing personalized and precise molecular insights, the company continues to push the frontier of cancer diagnostics and treatment management, aiming to ultimately improve patient outcomes across various cancer types.
For the full details of the MCC study, interested parties can refer to the Journal of Clinical Oncology.
Conclusion:’
Natera Inc. is making significant strides with its Signatera MRD test, cementing its utility in challenging cancer types like Merkel cell carcinoma and expanding its application to gastroesophageal cancer through the DECIPHER trial. These advancements underline the transformative potential of personalized, tumor-informed MRD testing in improving cancer surveillance and guiding treatment strategies.
Comments